IT202200007988A1 - 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation - Google Patents

4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation Download PDF

Info

Publication number
IT202200007988A1
IT202200007988A1 IT102022000007988A IT202200007988A IT202200007988A1 IT 202200007988 A1 IT202200007988 A1 IT 202200007988A1 IT 102022000007988 A IT102022000007988 A IT 102022000007988A IT 202200007988 A IT202200007988 A IT 202200007988A IT 202200007988 A1 IT202200007988 A1 IT 202200007988A1
Authority
IT
Italy
Prior art keywords
preparation
anticancer agents
polymerase inhibitors
chromone derivatives
chromone
Prior art date
Application number
IT102022000007988A
Other languages
Italian (it)
Inventor
Vivo Marco De
Nicoletta Brindani
Federico Munafo'
Michela Nigro
Original Assignee
Fondazione St Italiano Tecnologia
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione St Italiano Tecnologia, Univ Bologna Alma Mater Studiorum filed Critical Fondazione St Italiano Tecnologia
Priority to IT102022000007988A priority Critical patent/IT202200007988A1/en
Priority to PCT/IB2023/054098 priority patent/WO2023203535A1/en
Publication of IT202200007988A1 publication Critical patent/IT202200007988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102022000007988A 2022-04-22 2022-04-22 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation IT202200007988A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102022000007988A IT202200007988A1 (en) 2022-04-22 2022-04-22 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation
PCT/IB2023/054098 WO2023203535A1 (en) 2022-04-22 2023-04-21 4-chromone derivatives as n-polymerase inhibitors for use in the treatment platinum resistant metastatic neoplasm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000007988A IT202200007988A1 (en) 2022-04-22 2022-04-22 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation

Publications (1)

Publication Number Publication Date
IT202200007988A1 true IT202200007988A1 (en) 2023-10-22

Family

ID=82608476

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000007988A IT202200007988A1 (en) 2022-04-22 2022-04-22 4-chromone derivatives as polymerase inhibitors - as anticancer agents and method for their preparation

Country Status (2)

Country Link
IT (1) IT202200007988A1 (en)
WO (1) WO2023203535A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076863A1 (en) 2005-01-20 2006-07-27 Shanghai Gloriayx Biopharmaceuticals Co., Ltd The synergistically pharmaceutical composition for inhibiting tumor
US20100035887A1 (en) 2007-02-06 2010-02-11 Ricciardi Robert P Therapeutic compounds for blocking dna synthesis of pox viruses
WO2011099978A1 (en) * 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Chromone inhibitors of s-nitrosoglutathione reductase
WO2017132928A1 (en) 2016-02-04 2017-08-10 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
WO2019008537A1 (en) * 2017-07-05 2019-01-10 Vera Salus Ricerca S.R.L. Medical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076863A1 (en) 2005-01-20 2006-07-27 Shanghai Gloriayx Biopharmaceuticals Co., Ltd The synergistically pharmaceutical composition for inhibiting tumor
US20100035887A1 (en) 2007-02-06 2010-02-11 Ricciardi Robert P Therapeutic compounds for blocking dna synthesis of pox viruses
WO2011099978A1 (en) * 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Chromone inhibitors of s-nitrosoglutathione reductase
WO2017132928A1 (en) 2016-02-04 2017-08-10 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
WO2019008537A1 (en) * 2017-07-05 2019-01-10 Vera Salus Ricerca S.R.L. Medical compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CATANZARO DANIELA ET AL: "Cell Cycle Control by Natural Phenols in Cisplatin-Resistant Cell Lines", NATURAL PRODUCT COMMUNICATIONS, vol. 9, no. 10, 1 October 2014 (2014-10-01), US, XP093003570, ISSN: 1934-578X, DOI: 10.1177/1934578X1400901015 *
EUROPEAN JOURNAL OF MEDI CAL CHEMISTRY, vol. 180, 2019, pages 350 - 366
LUO HAITAO ET AL: "Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 11 May 2010 (2010-05-11), pages 16, XP021077239, ISSN: 1475-2867, DOI: 10.1186/1475-2867-10-16 *
PAPACHRISTOU FOTINI ET AL: "Differential effects of cisplatin combined with the flavonoid apigenin on HepG2, Hep3B, and Huh7 liver cancer cell lines", MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, vol. 866, 1 June 2021 (2021-06-01), NL, pages 503352, XP093003646, ISSN: 1383-5718, DOI: 10.1016/j.mrgentox.2021.503352 *
SHI ET AL.: "Synthesis, biological evaluation and SAR analysis of O-alkylated analogues of quercetin for anticancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, 2014, pages 4424 - 4427, XP029053337, DOI: 10.1016/j.bmcl.2014.08.006
SUN LEI ET AL: "Synthesis, characterization and antioxidant activity of quercetin derivatives", SYNTHETIC COMMUNICATIONS, vol. 51, no. 19, 23 August 2021 (2021-08-23), US, pages 2944 - 2953, XP055943921, ISSN: 0039-7911, DOI: 10.1080/00397911.2021.1942059 *
ZAFAR ET AL.: "A small-molecule inhibitor of Human DNA Polymerase η Potentiates the effects of cisplatin in tumor cells", BIOCHEMISTRY, vol. 57, no. 7, 20 February 2018 (2018-02-20), pages 1262 - 1273
ZHANG YU ET AL: "Flavonoids from Chinese bayberry leaves induced apoptosis and G1 cell cycle arrest via Erk pathway in ovarian cancer cells", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 147, 1 March 2018 (2018-03-01), AMSTERDAM, NL, pages 218 - 226, XP093003652, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.01.084 *

Also Published As

Publication number Publication date
WO2023203535A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
CL2020000632A1 (en) Composition and method for the treatment of autism.
CL2015000530A1 (en) Cyclic derivative compounds ether pyrazol-4-yl-heterocyclyl-carboxamide, as pim kinase inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer, immunological disorders, cardiovascular diseases, viral infection, inflammation, metabolic disorders / endocrine function and neurological disorders.
CO2017001035A2 (en) "2- (morpholin-4-yl) -1,7-substituted naphthyridines, compositions and pharmaceutical combinations comprising them, and intermediate compounds
FR3052452B1 (en) NOVEL PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
UY36684A (en) APJ RECEIVER TRIAZOL AGONISTS
MA39809A (en) 4 'SUBSTITUTED NUCLEOSIDE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS
BR112018003212A2 (en) diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation
UY33886A (en) C-17 AND C-3 TRITERPENOIDS MODIFIED WITH INHIBITING ACTIVITY OF HIV MATURATION
CO2018008846A2 (en) Carboxamide derivatives useful as rsk inhibitors
GT201700107A (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND OESTEOARTHRITIS
BR112016022394A2 (en) PHARMACEUTICALLY ACCEPTABLE COMPOSITION, COMPOSITION IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE INJECTABLE SOLUTION, USE OF THE COMPOSITION, AND METHOD FOR PREPARING THE PHARMACEUTICALLY ACCEPTABLE INJECTABLE COMPOSITION
BR112017003346A2 (en) pyrazolopyridine derivatives, their uses, and pharmaceutical composition
ITMI20131693A1 (en) DERIVATIVES OF 1,4-CYCLOHEXYLAMINE AND THEIR PREPARATION
SV2017005466A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
CL2017002474A1 (en) Anthelmintic combinations and their methods of use
BR112016025876A8 (en) composition, processes for preparing a microcapsule and a unit dosage form, unit dosage form, microcapsule, product, use of a composition, and, method of treating a condition associated with vitamin k1 or k2
BR112016016870A8 (en) icariin derivatives, their uses, and pharmaceutical composition
CO2019007776A2 (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
CR20150653A (en) NEW COMPOUNDS FOR CANCER TREATMENT
MX2020004810A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases.
UY36070A (en) TRITERPENOIDS WITH INHIBITING ACTIVITY OF HIV MATURATION
CR20160133A (en) SUBSTITUTED PHENYLALANINE DERIVATIVES
IT201900023895A1 (en) COMBINATION INCLUDING THE BH3-MIMETIC COMPOUND ABT-199 (VENETOCLAX) AND AT LEAST ONE INHIBITOR OF THE PRODUCTION OF NADPH AND / OR ITS SALTS OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THIS COMBINATION OF NADPH AND / OR ITS SALTS OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS INCLUDING THIS COMBINATION OF NADPH-LINKU, PREFERABLY IN THE TREATMENT OF DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
CO2017002813A2 (en) Stabilized derivatives of adrenomedullin and their use